Navigation Links
Anaptysbio Expands Leadership Team With Addition Of Dr. Andrew J. Mcknight
Date:8/8/2012

SAN DIEGO, Aug. 8, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately held therapeutic antibody company, today announced the addition of Andrew J. McKnight, Ph.D. as Senior Director, Target Biology.  Dr. McKnight comes to AnaptysBio with extensive experience in the design and development of novel therapeutic antibodies across a variety of therapeutic areas.  Working together with David J. King, Ph.D., AnaptysBio's chief scientific officer, Dr. McKnight will be leading the advancement of AnaptysBio's current and future internal pipeline programs. 

(Logo: http://photos.prnewswire.com/prnh/20111205/SF16052LOGO)

AnaptysBio's primary objective is the advancement of novel therapeutic antibody programs generated using the Company's proprietary SHM-XEL platform.  As the first company to replicate somatic hypermutation (SHM) in vitro for antibody discovery, AnaptysBio's SHM-XEL platform is uniquely positioned to generate therapeutic antibodies with unique functionality.  The Company is currently pursuing differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders and antibody-drug conjugate applications.  AnaptysBio's internal programs are independent of the Company's partnerships with Merck, Roche, Novartis, Celgene, Gilead and DARPA. 

Dr. McKnight comes to AnaptysBio most recently from Pfizer's Biotherapeutics group, where he directed numerous internal and partnered antibody development projects.  Prior to Pfizer, Dr. McKnight led antibody projects at UCB-Celltech. Dr. McKnight received his doctorate from University of Oxford and was a postdoctoral fellow at Harvard Medical School. 

"We are delighted to add Andrew's target biology experience to AnaptysBio's research and development team," said Hamza Suria, AnaptysBio's president and chief executive officer. "The unique strengths of our SHM-XEL platform provide AnaptysBio with distinct advantages in the design and discovery of novel therapeutic antibodies."

About AnaptysBio

Founded in 2005, AnaptysBio, Inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies.  AnaptysBio's proprietary SHM-XEL platform, which couples fully human antibody libraries with in vitro somatic hypermutation (SHM) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.  By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, functionality, cross-reactivity and epitope diversity.   AnaptysBio has established broad intellectual property around the use of SHM and is currently building a pipeline of novel therapeutic antibody product candidates. The Company has previously announced pharma partnerships with Merck, Roche, Novartis, Celgene and Gilead.  Major investors in AnaptysBio include founding investor Avalon Ventures, as well as Alloy Ventures, Frazier Healthcare Ventures, and Novo A/S. For more information, visit www.anaptysbio.com.


'/>"/>
SOURCE AnaptysBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Asthmapolis Expands Dignity Health Study to Include Mercy Medical Group Patients
2. Hospira Expands Board of Directors With Election of Dennis M. Fenton
3. The MED Group Expands MED Suppliers Network to add Ventilator Program
4. Integrity Life Sciences Expands Orthotic Options for Domestic and International Customers
5. Practice Fusion Expands Executive Team with Addition of General Counsel and Associate VP of Corporate Development
6. OceanGate Inc. Expands Board of Directors with Two Key Appointments
7. ViiV Healthcare Expands Commitment to Addressing Gaps in Paediatric HIV Research, Care and Treatment
8. Acquisition of Navigenics Expands Life Technologies Capabilities in Diagnostics
9. Echo Therapeutics Expands License Agreement with Ferndale Pharma
10. Tris Pharma Expands Manufacturing Capacity and Strengthens Supply Chain to Support New and Pending Approvals
11. Dr. Jills Foot Pads Secures GSA Schedule and Expands to Service VA and Federal Agencies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at www.diabetesscholars.org ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
(Date:6/23/2016)... WASHINGTON , June 23, 2016  The ... Pharmaceuticals has joined the health policy research organization ... Steven Romano , MD, senior vice president and ... his company,s representative on the NPC Board of ... are pleased that Mallinckrodt has joined us in ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery Institute ... pageant as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, ... , Dr. Olson says the decision to support the pageant in an official ...
(Date:6/24/2016)... ... 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially launched its site, ... matching users with high quality water pipes within an ideal price range. The site ... was founded by two brothers, Nick and Mike Hunter, who use medical cannabis to ...
Breaking Medicine News(10 mins):